SEATTLE, WA / USMarketWire/ November 3, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.
APVO436 is a novel anti-CD123 x anti-CD3 targeted investigational bispecific antibody therapy being evaluated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), in a Phase 1/1b open-label, dose-escalation study evaluating the safety and pharmacokinetic profile.
Aptevo is pleased to announce that, based on preliminary data, a patient in cohort 6 of the clinical trial has shown complete remission.
Patient bone marrow blasts decreased from 29% at the screen to 6% after the first cycle of treatment, and to 0% after the second cycle of treatment; and,
The patient’s platelet count and absolute neutrophil count (ANC) met complete remission criteria (CR).
“We are greatly encouraged by the complete remission in the patient in cohort 6, which is a wonderful outcome for them,” said Marvin White, President, and CEO of Aptevo Therapeutics. “We are now in a critical phase of the study, as pharmacokinetic modeling suggests that dosing in cohorts 5 through 8 is in a therapeutic range, which could result in the potential clinical activity of the drug. We look forward to continuing the dose-escalation and monitoring potential clinical responses as we advance through the upcoming dose cohorts,” concluded Mr. White.
APVO436 was built on Aptevo’s next-generation proprietary ADAPTIR™ protein therapeutic platform. Focused on generating novel, targeted bispecific antibody-based immunotherapies for cancer the ADAPTIR™ platform offers key advantages over other bispecific formats, derived in part from the flexible and modular nature of the ADAPTIR™ structure.
Aptevo believes that its differentiated ADAPTIR™ bispecific technology platform has the potential to offer a more convenient and cost-effective solution compared to other immunotherapies such as CAR-T therapies. While CAR-T therapies have proven effective in generating robust and durable treatment responses, they remain challenging and expensive to manufacture and administer to patients. In contrast, bispecific technologies may represent a simpler, more competitive ‘off-the-shelf’ solution in the rapidly advancing field of cancer immunotherapy.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company’s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company’s versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com
984 total views, 1 views today